Form D · Biotechnology
ERAD Therapeutics Inc.
Caledon, A6 · CIK 0001655883
Offering snapshot reported Nov 9, 2015 · SEC filing
- Reported sold
- $84.3K Offering amount: $175K
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $19.8K Reported outside-investor minimum
- First sale
- Oct 23, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 9, 2015 | Initial | $84,283 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 05
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-250869
No agents used or sales commissions paid
Source: Form D, filed Nov 9, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Bender | Director |
| Craig Alexander Sibley | Director, Executive |
| George Spitalny | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6 Cedar Drive
Caledon, A6, L7K 1H6
Caledon, A6, L7K 1H6